200,000 LifeMD (LFMD) RSUs awarded to marketing head

Rhea-AI Filing Summary

Pisano Christopher A reported acquisition or exercise transactions in this Form 4 filing.

LifeMD, Inc. reported that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 shares of common stock in the form of restricted stock units on March 30, 2026. The award carries no purchase price.

According to the vesting terms, 50,000 units vest on the grant date, and an additional 50,000 units also vest on the grant dateMarch 30, 2027. A further 50,000 units vest on March 30, 2027, with the remaining units vesting on March 30, 2028, aligning the compensation with continued service at the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pisano Christopher A

Role Chief Marketing Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	200,000	$0.00	--

Holdings After Transaction: Common Shares — 200,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 200,000 shares Grant price per share: $0.00 per share Immediate vesting portion: 50,000 units +4 more

7 metrics

RSU grant size 200,000 shares Restricted stock units granted to CMO on March 30, 2026

Grant price per share $0.00 per share Reported transaction price for awarded common shares

Immediate vesting portion 50,000 units Restricted stock units vesting on grant date

Grant-date clawback-eligible portion 50,000 units Vest on grant date but subject to clawback if not employed through March 30, 2027

2027 vesting tranche 50,000 units Restricted stock units vesting on March 30, 2027

2028 vesting tranche Remaining units Restricted stock units vesting on March 30, 2028

Shares held after transaction 200,000 shares Total direct holdings following the award

Key Terms

restricted stock units, clawback, Chief Marketing Officer, grant, award, or other acquisition

4 terms

restricted stock units financial

"The grant of restricted stock units vest 50,000 on grant date"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

clawback financial

"which are subject to clawback in their entirety should the Owner not be employed"

A clawback is a contractual or legal right to recover money that was already paid out—often executive bonuses, incentives, or erroneous payments—when certain conditions change, such as fraud, accounting mistakes, or failure to meet performance targets. It matters to investors because clawbacks protect shareholder value by discouraging risky or misleading behavior, can affect future cash flow and executive incentives, and signal stronger governance, much like a store recalling a refund after discovering it was issued in error.

Chief Marketing Officer financial

"reporting person serves as Chief Marketing Officer of LifeMD, Inc."

A chief marketing officer (CMO) is the senior executive who leads a company's efforts to attract and keep customers by managing brand image, advertising, pricing signals and market research. Investors monitor the CMO because their strategies directly affect sales growth, customer loyalty and the success of product launches—think of the CMO as the person designing a store’s storefront and promotions to draw and retain shoppers, which impacts revenue and valuation.

grant, award, or other acquisition financial

"transaction code A is described as Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pisano Christopher A

(Last) (First) (Middle)

C/O LIFEMD

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/30/2026		A		200,000(1)	A	$0	200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant of restricted stock units vest 50,000 on grant date, an additional 50,000 restricted stock units vest on grant date, which are subject to clawback in their entirety should the Owner not be employed by the Issuer through March 30, 2027 for any reason, 50,000 on March 30, 2027 and the remainder on March 30, 2028.

	/s/ Christopher A. Pisano	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LifeMD (LFMD) disclose for Christopher A. Pisano?

LifeMD disclosed that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 restricted stock units of common shares. The award was reported at a price of $0.00 per share, reflecting compensation rather than an open-market purchase or sale, and increases his direct holdings.

How do the 200,000 LifeMD (LFMD) restricted stock units vest?

The 200,000 restricted stock units vest in stages. 50,000 units vest on the grant date, another 50,000 units also vest on the grant date, 50,000 units vest on March 30, 2027, and the remaining units vest on March 30, 2028, encouraging multi‑year retention.

What is the clawback condition on Christopher Pisano’s LifeMD (LFMD) award?

An additional 50,000 restricted stock units that vest on the grant date are subject to clawback if Pisano is not employed by LifeMD through March 30, 2027. If employment ends before then, those clawback‑eligible units can be forfeited, tying part of the grant to continued service.

Is the LifeMD (LFMD) grant to Christopher Pisano a market purchase or compensation award?

The transaction is a compensation award, not a market purchase. It is coded as a grant or award acquisition at a price of $0.00 per share, reflecting restricted stock units issued by LifeMD as part of Pisano’s executive compensation package rather than cash-funded buying or selling.

How many LifeMD (LFMD) shares does Christopher Pisano hold after this Form 4 transaction?

After this transaction, Christopher Pisano is reported as directly holding 200,000 common shares linked to the restricted stock unit grant. This figure reflects his position following the award and shows the scale of equity-based compensation connected to his Chief Marketing Officer role.